Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02601378




Registration number
NCT02601378
Ethics application status
Date submitted
6/11/2015
Date registered
10/11/2015
Date last updated
29/09/2022

Titles & IDs
Public title
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
Scientific title
A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma
Secondary ID [1] 0 0
CLXS196X2101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Uveal Melanoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Malignant melanoma
Cancer 0 0 0 0
Other cancer types
Eye 0 0 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - LXS196
Treatment: Drugs - LXS196 and HDM201

Experimental: LXS196 as a single agent - About 68 patients will be enrolled in dose escalation and expansion

Experimental: LXS196 in combination with HDM201 - about 44 patients to be enrolled in dose escalation and expansion


Treatment: Drugs: LXS196
LXS196 as a single agent

Treatment: Drugs: LXS196 and HDM201
LXS196 in combination with HDM201
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of dose limiting toxicities (DLTs) (Dose escalation only)
Timepoint [1] 0 0
Cycle 1 in dose escalation
Primary outcome [2] 0 0
Incidence and severity of adverse events and serious adverse events, including changes in laboratory parameters, vital signs and ECGs graded as per NCI CTCAE version 4.03 (All patients)
Timepoint [2] 0 0
Continuously throughout the study until 30 days after treatment discontinuation
Primary outcome [3] 0 0
Dose interruptions, reductions and dose intensity
Timepoint [3] 0 0
Continuously throughout the study until 30 days after treatment discontinuation
Secondary outcome [1] 0 0
Overall response rate (ORR) per RECIST version 1.1 criteria
Timepoint [1] 0 0
From baseline, every 2 cycles until cycle 11, then every 3 cycles afterwards until disease progression or withdrawal of consent up to 12 months
Secondary outcome [2] 0 0
Plasma LXS196 concentration-time profiles as a single agent
Timepoint [2] 0 0
Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1
Secondary outcome [3] 0 0
Modulation of signaling molecules downstream of PKC
Timepoint [3] 0 0
Baseline and Cycle 1 Day 15
Secondary outcome [4] 0 0
Progression free survival (PFS) per RECIST version 1.1 criteria
Timepoint [4] 0 0
From baseline, every 2 cycles until cycle 11, then every 3 cycles afterwards until disease progression or withdrawal of consent up to 12 months
Secondary outcome [5] 0 0
Plasma PK parameters of LXS196 as a single agent:AUC
Timepoint [5] 0 0
Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1
Secondary outcome [6] 0 0
Plasma PK parameters of LXS196 as a single agent: Cmax
Timepoint [6] 0 0
Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1
Secondary outcome [7] 0 0
Plasma PK parameters of LXS196 as a single agent: Tmax
Timepoint [7] 0 0
Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1
Secondary outcome [8] 0 0
Plasma PK parameters of LXS196 as a single agent: t1/2
Timepoint [8] 0 0
Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1
Secondary outcome [9] 0 0
Plasma PK parameters of LXS196 as a single agent: Racc
Timepoint [9] 0 0
Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1
Secondary outcome [10] 0 0
Plasma HDM201 concentration-time profiles
Timepoint [10] 0 0
Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day 1
Secondary outcome [11] 0 0
Plasma PK parameters of HDM201: AUC
Timepoint [11] 0 0
Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day 1
Secondary outcome [12] 0 0
Plasma PK parameters of HDM201: Cmax
Timepoint [12] 0 0
Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day 1
Secondary outcome [13] 0 0
Plasma PK parameters of HDM201: Tmax
Timepoint [13] 0 0
Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day 1
Secondary outcome [14] 0 0
Plasma PK parameters of HDM201: t1/2
Timepoint [14] 0 0
Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day 1
Secondary outcome [15] 0 0
Plasma LXS196 concentration-time profiles in combination with HDM201
Timepoint [15] 0 0
Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day1
Secondary outcome [16] 0 0
Plasma PK parameters of LXS196 in combination with HDM201:AUC
Timepoint [16] 0 0
Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day1
Secondary outcome [17] 0 0
Plasma PK parameters of LXS196 in combination with HDM201: Cmax
Timepoint [17] 0 0
Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day1
Secondary outcome [18] 0 0
Plasma PK parameters of LXS196 in combination with HDM201: Tmax
Timepoint [18] 0 0
Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day1
Secondary outcome [19] 0 0
Plasma PK parameters of LXS196 in combination with HDM201: t1/2
Timepoint [19] 0 0
Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day1
Secondary outcome [20] 0 0
Plasma PK parameters of LXS196 in combination with HDM201: Racc
Timepoint [20] 0 0
Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day1
Secondary outcome [21] 0 0
LXS196 plasma protein binding as a single agent
Timepoint [21] 0 0
Cycle 1 Day 1, 2, 15, 16
Secondary outcome [22] 0 0
LXS196 plasma protein content as a single agent
Timepoint [22] 0 0
Cycle 1, 2, 3 and 4 Day 1

Eligibility
Key inclusion criteria
Key

* Male or female patients =18 years of age
* Diagnosis of uveal melanoma with histological or cytological confirmed metastatic disease. Disease must be treatment naive or have progressed (radiologically or clinically) on most recent therapy.
* Willingness to provide newly obtained tumor tissue at baseline and on treatment unless contraindicated by medical risk in the opinion of the treating physician.
* Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as >10 mm with CT scan.
* ECOG performance status = 1

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Malignant disease other than that being treated in this study.
* Symptomatic or untreated CNS metastases or spinal cord compression. Brain metastasis must be stable with verification by imaging .
* Impaired cardiac function or clinically significant cardiac diseases
* History of thromboembolic or cerebrovascular events within the last 6 months, including transient ischemic attack, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism (applicable to combination part only).
* Patients who are receiving treatment with medications that cannot be discontinued prior to study entry and that are considered to be any of the following:
* known and possible risk for QT prolongation
* known to be strong inducers or inhibitors of CYP3A4/5 (for single agent part); known to be moderate to strong inducers or inhibitors of CYP3A4/5 (for combination part)
* known to be inducers or inhibitors of P-gp
* known to be substrates of CYP3A4/5 and P-gp with a narrow therapeutic index
* Patients with abnormal laboratory values, defined as any of the following:
* AST or ALT > 3 times ULN, AST or ALT > 5 times ULN for patients with liver metastases.
* Total bilirubin > 1.5 x ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin > 3.0 x ULN or direct bilirubin > 1.5 x ULN.
* Absolute neutrophil count (ANC) = 1.5 x109/L.
* Platelets = 100 x 109/L.
* Hemoglobin (Hgb) = 90 g/L (9 g/dL).
* Creatinine > 1.5 x ULN
* Patients receiving live vaccines due to the expected bone marrow toxicity (applicable to combination part only).
* Patients treated with growth factors targeting the myeloid lineage (e.g. G-CSF, GM-CSF and M-CSF) within 2 weeks of starting study treatment. (applicable to combination part only).

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/02/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
7/01/2022
Sample size
Target
Accrual to date
Final
107
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Novartis Investigative Site - Westmead
Recruitment postcode(s) [1] 0 0
2145 - Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
New York
Country [2] 0 0
France
State/province [2] 0 0
Paris
Country [3] 0 0
Netherlands
State/province [3] 0 0
Leiden
Country [4] 0 0
Norway
State/province [4] 0 0
Oslo
Country [5] 0 0
Spain
State/province [5] 0 0
Madrid

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic uveal melanoma.
Trial website
https://clinicaltrials.gov/study/NCT02601378
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02601378